These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
118 related articles for article (PubMed ID: 12610054)
1. Safety and efficacy of repaglinide in type 2 diabetic patients with and without impaired renal function. Hasslacher C; Diabetes Care; 2003 Mar; 26(3):886-91. PubMed ID: 12610054 [TBL] [Abstract][Full Text] [Related]
2. A double-blind randomized comparison of meal-related glycemic control by repaglinide and glyburide in well-controlled type 2 diabetic patients. Damsbo P; Clauson P; Marbury TC; Windfeld K Diabetes Care; 1999 May; 22(5):789-94. PubMed ID: 10332683 [TBL] [Abstract][Full Text] [Related]
3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
4. Repaglinide in type 2 diabetes: a 24-week, fixed-dose efficacy and safety study. Jovanovic L; Dailey G; Huang WC; Strange P; Goldstein BJ J Clin Pharmacol; 2000 Jan; 40(1):49-57. PubMed ID: 10631622 [TBL] [Abstract][Full Text] [Related]
5. Single- and multiple-dose pharmacokinetics of repaglinide in patients with type 2 diabetes and renal impairment. Schumacher S; Abbasi I; Weise D; Hatorp V; Sattler K; Sieber J; Hasslacher C Eur J Clin Pharmacol; 2001 May; 57(2):147-52. PubMed ID: 11417447 [TBL] [Abstract][Full Text] [Related]
6. Pre-prandial vs. post-prandial capillary glucose measurements as targets for repaglinide dose titration in people with diet-treated or metformin-treated Type 2 diabetes: a randomized controlled clinical trial. Gerstein HC; Garon J; Joyce C; Rolfe A; Walter CM Diabet Med; 2004 Nov; 21(11):1200-3. PubMed ID: 15498086 [TBL] [Abstract][Full Text] [Related]
7. [Antidiabetic drug at every meal. Repaglinide is especially recommended for slender type 2 diabetic patients]. Landgraf R MMW Fortschr Med; 2000 Jul; 142(28-29):29-30. PubMed ID: 10959157 [TBL] [Abstract][Full Text] [Related]
8. Dose titration of repaglinide in patients with inadequately controlled type 2 diabetes. Kølendorf K; Eriksson J; Birkeland KI; Kjellström T; Hreidarsson AB Diabetes Res Clin Pract; 2004 Apr; 64(1):33-40. PubMed ID: 15036825 [TBL] [Abstract][Full Text] [Related]
9. Flexible meal-related dosing with repaglinide facilitates glycemic control in therapy-naive type 2 diabetes. Moses RG; Gomis R; Frandsen KB; Schlienger JL; Dedov I Diabetes Care; 2001 Jan; 24(1):11-5. PubMed ID: 11194214 [TBL] [Abstract][Full Text] [Related]
10. Optimizing insulin secretagogue therapy in patients with type 2 diabetes: a randomized double-blind study with repaglinide. Schmitz O; Lund S; Andersen PH; Jønler M; Pørksen N Diabetes Care; 2002 Feb; 25(2):342-6. PubMed ID: 11815507 [TBL] [Abstract][Full Text] [Related]
11. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Goldberg RB; Einhorn D; Lucas CP; Rendell MS; Damsbo P; Huang WC; Strange P; Brodows RG Diabetes Care; 1998 Nov; 21(11):1897-903. PubMed ID: 9802740 [TBL] [Abstract][Full Text] [Related]
12. Beta-cell response during a meal test: a comparative study of incremental doses of repaglinide in type 2 diabetic patients. Cozma LS; Luzio SD; Dunseath GJ; Underwood PM; Owens DR Diabetes Care; 2005 May; 28(5):1001-7. PubMed ID: 15855557 [TBL] [Abstract][Full Text] [Related]
13. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. Johansen OE; Birkeland KI Am J Cardiovasc Drugs; 2007; 7(5):319-35. PubMed ID: 17953471 [TBL] [Abstract][Full Text] [Related]
14. Nateglinide versus repaglinide for type 2 diabetes mellitus in China. Li C; Xia J; Zhang G; Wang S; Wang L Acta Diabetol; 2009 Dec; 46(4):325-33. PubMed ID: 19183841 [TBL] [Abstract][Full Text] [Related]
16. Effect of repaglinide, administered two or three times daily for 3 months, on glycaemic control in Japanese patients with type 2 diabetes mellitus. Kamiyama H; Aoki K; Nakajima S; Shinoda K; Kamiko K; Taguri M; Terauchi Y J Int Med Res; 2014 Oct; 42(5):1150-60. PubMed ID: 25015763 [TBL] [Abstract][Full Text] [Related]
17. Repaglinide treatment amplifies first-phase insulin secretion and high-frequency pulsatile insulin release in Type 2 diabetes. Hollingdal M; Sturis J; Gall MA; Damsbo P; Pincus S; Veldhuis JD; Pørksen N; Schmitz O; Juhl CB Diabet Med; 2005 Oct; 22(10):1408-13. PubMed ID: 16176204 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of repaglinide in subjects with renal impairment. Marbury TC; Ruckle JL; Hatorp V; Andersen MP; Nielsen KK; Huang WC; Strange P Clin Pharmacol Ther; 2000 Jan; 67(1):7-15. PubMed ID: 10668848 [TBL] [Abstract][Full Text] [Related]
19. Repaglinide: a short acting insulin secretagogue for postprandial hyperglycaemia. Ambavane V; Patil R; Ainapure SS J Postgrad Med; 2002; 48(3):246-8. PubMed ID: 12432213 [No Abstract] [Full Text] [Related]
20. Clinical study of repaglinide efficacy and safety in type 2 diabetes mellitus patients with blood glucose levels inadequately controlled by sitagliptin. Kawamori R; Kaku K; Hanafusa T; Ioriya K; Kageyama S; Hotta N J Diabetes Investig; 2016 Mar; 7(2):253-9. PubMed ID: 27042279 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]